Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	-	31/12/2017

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-23.08%	+41.41%	-58.43%	-79.04%	11.25M
LONZA GROUP AG	+0.58%	+2.06%	+3.90%	+10.40%	50.73B
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+391.53%	+591.38%	39.73B
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+27.67%	-3.89%	34.69B
BEONE MEDICINES AG	-1.36%	+0.35%	+19.34%	+58.83%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+37.03%	26.76B
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	16.8B
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+66.38%	+125.61%	15.37B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.80%	+19.56%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+11.43%	-29.93%	12.85B
Average	-2.71%	+3.39%	+53.18%	+81.10%	24.39B
Weighted average by Cap.	-0.48%	-0.23%	+82.74%	+126.13%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	SEK 0.7000	-23.08%	22,449,804
09/07/26	SEK 0.9100	-11.82%	14,741,167
08/07/26	SEK 1.032	-26.29%	76,153,518
07/07/26	SEK 1.400	+191.67%	97,009,916
06/07/26	SEK 0.4800	-3.03%	1,043,697

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 10/07/2026 BST			5-day change	1st Jan Change
0.7000 ^SEK	-23.08%		+41.41%	-15.56%

Market Cap	108M 11.25M 9.84M 9.08M 8.38M 15.91M 1.07B 16.18M 42.6M 529M 42.25M 41.33M 1.82B	P/E 2026 *	-2.59x	P/E 2027 *	-1.84x
Enterprise Value	92.47M 9.59M 8.39M 7.74M 7.15M 13.56M 915M 13.79M 36.31M 451M 36.02M 35.23M 1.55B	EV / Sales 2026 *	2.95x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	-23.08%
1 week	+41.41%
Current month	+41.13%
1 month	+53.01%
3 months	+18.64%
6 months	-12.39%
Current year	-15.56%

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.48	1.61
1 month	0.45	1.61
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.79
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.25M 2.84M 2.62M 2.42M 4.6M 310M 4.68M 12.31M 153M 12.21M 11.95M 525M	-
Net income	-3.2M -332K -290K -268K -247K -469K -31.66M -477K -1.26M -15.6M -1.25M -1.22M -53.62M	-50.35M -5.22M -4.57M -4.21M -3.89M -7.39M -498M -7.51M -19.77M -245M -19.61M -19.18M -844M
Net Debt	-16M -1.66M -1.45M -1.34M -1.24M -2.35M -158M -2.39M -6.28M -77.98M -6.23M -6.1M -268M	-19M -1.97M -1.72M -1.59M -1.47M -2.79M -188M -2.83M -7.46M -92.61M -7.4M -7.24M -318M